This report identifies the global premenstrual syndrome treatment market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to global premenstrual syndrome treatment market.
Geographically North America dominated global premenstrual syndrome treatment market due to higher awareness about such diseases, higher registered cases due to life style related health issues and well developed healthcare infrastructure. North America was followed by Europe and Asia-Pacific as second and third largest consumer of premenstrual syndrome treatment. Asia Pacific is projected to have fastest growth, owing to rapidly expanding healthcare infrastructure, increasing awareness especially in the major regional economies such as India and China in the region.
This report segments global premenstrual syndrome treatment market on the basis of treatment type and regional market as follows:
On the basis of treatment type this report on global premenstrual syndrome treatment market is segmented as follows, covering major segments as follows: Painkillers, Oral contraceptive pills, Estrogen-only patches and implants, Gonadotropin-releasing hormone (GnRH) analogues, Selective serotonin reuptake inhibitors (SSRIs)
This report on premenstrual syndrome treatment has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region
This report identifies all the major companies operating in the premenstrual syndrome treatment market. Some of the major companies’ profiles in detail are as follows:
Pherin Pharmaceuticals, Inc.
Umecrine Mood AB
MetP Pharma AG
Bristol Meyer Squibb
Please Note: The report is to be delivered in 1-2 working days after an order is placed.
2. Executive Summary
3. Market Landscape
3.1. Market Share Analysis
3.2. Comparative Analysis
3.3. Product Benchmarking
3.4. End User Profiling
3.5. Top 5 Financials Analysis
4. Premenstrual Syndrome Treatment Market– Market Forces
4.1.1. Growing registered cases of PMS due to changing life style
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Degree of Competition
5. Premenstrual Syndrome Treatment Market – Strategic Analysis
5.1. Value Chain Analysis
5.2. Pricing Analysis
5.3. Opportunities Analysis
5.4. Product/Market Life cycle Analysis
5.5. Suppliers & Distributors
6. Premenstrual Syndrome Treatment Market, By Treatment
6.2. Oral contraceptive pills
6.3. Estrogen-only patches & implants
6.4. Gonadotropin-releasing hormone (GnRH) analogues
6.5. Selective serotonin reuptake inhibitors (SSRIs)
7. Premenstrual Syndrome Treatment Market, By Geography
7.1.7. Rest of Europe
7.2. Asia Pacific
7.2.4. South Korea
7.2.5. Rest of Asia-Pacific
7.3. North America
7.4. Rest of the World (RoW)
7.4.2. Rest of RoW
8. Premenstrual Syndrome Treatment – Market Entropy
8.2. Technological Developments
8.3. Merger & Acquisitions, and Joint Ventures
8.4. Supply- Contract
9. Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)
9.1. Pherin Pharmaceuticals, Inc.
9.2. DEKK-TEC, Inc.
9.3. Umecrine Mood AB
9.4. MetP Pharma AG
9.5. Bristol Meyer Squibb
9.6. Merck and Co.
9.7. Novartis AG
9.8. Pfizer, Inc.
9.9. Cipla Laboratories.
9.10. Dr. Reddy’s Laboratories Ltd
* More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"Financials would be provided on a best efforts basis for private companies"
10.3. Research Methodology
10.5. Compilation of Expert Insights